4.5 Article

Clinical and computed tomographic predictors of chronic bronchitis in COPD: a cross sectional analysis of the COPDGene study

Journal

RESPIRATORY RESEARCH
Volume 15, Issue -, Pages -

Publisher

BIOMED CENTRAL LTD
DOI: 10.1186/1465-9921-15-52

Keywords

Chronic bronchitis; Chronic obstructive pulmonary disease; Airway thickening; Asthma

Funding

  1. NHLBI [R01 HL089856, R01 HL08989, K23HL094696-03]
  2. National Heart Lung and Blood Institute
  3. Abbott
  4. Astellas
  5. AstraZeneca
  6. Boerhinger-Ingelheim
  7. Coviden
  8. Dey
  9. Forest
  10. GlaxoSmithKline
  11. Merck
  12. MedImmune
  13. NABI
  14. Novartis
  15. Pfizer
  16. Respironics
  17. Sepracor
  18. Sequal
  19. Talecris
  20. Pearl
  21. Actelion
  22. Aeris
  23. Therapeutics
  24. Pulmonx
  25. PneumRx

Ask authors/readers for more resources

Background: Chronic bronchitis (CB) has been related to poor outcomes in Chronic Obstructive Pulmonary Disease (COPD). From a clinical standpoint, we have shown that subjects with CB in a group with moderate to severe airflow obstruction were younger, more likely to be current smokers, male, Caucasian, had worse health related quality of life, more dyspnea, and increased exacerbation history compared to those without CB. We sought to further refine our clinical characterization of chronic bronchitics in a larger cohort and analyze the CT correlates of CB in COPD subjects. We hypothesized that COPD patients with CB would have thicker airways and a greater history of smoking, acute bronchitis, allergic rhinitis, and occupational exposures compared to those without CB. Methods: We divided 2703 GOLD 1-4 subjects in the Genetic Epidemiology of COPD (COPDGene (R)) Study into two groups based on symptoms: chronic bronchitis (CB+, n = 663, 24.5%) and no chronic bronchitis (CB-, n = 2040, 75.5%). Subjects underwent extensive clinical characterization, and quantitative CT analysis to calculate mean wall area percent (WA%) of 6 segmental airways was performed using VIDA PW2 (http://www.vidadiagnostics.com). Square roots of the wall areas of bronchi with internal perimeters 10 mm and 15 mm (Pi10 and Pi15, respectively), % emphysema, % gas trapping, were calculated using 3D Slicer (http://www.slicer.org). Results: There were no differences in % emphysema (11.4 +/- 12.0 vs. 12.0 +/- 12.6%, p = 0.347) or % gas trapping (35.3 +/- 21.2 vs. 36.3 +/- 20.6%, p = 0.272) between groups. Mean segmental WA% (63.0 +/- 3.2 vs. 62.0 +/- 3.1%, p < 0.0001), Pi10 (3.72 +/- 0.15 vs. 3.69 +/- 0.14 mm, p < 0.0001), and Pi15 (5.24 +/- 0.22 vs. 5.17 +/- 0.20, p < 0.0001) were greater in the CB + group. Greater percentages of gastroesophageal reflux, allergic rhinitis, histories of asthma and acute bronchitis, exposures to dusts and occupational exposures, and current smokers were seen in the CB + group. In multivariate binomial logistic regression, male gender, Caucasian race, a lower FEV1%, allergic rhinitis, history of acute bronchitis, current smoking, and increased airway wall thickness increased odds for having CB. Conclusions: Histories of asthma, allergic rhinitis, acute bronchitis, current smoking, a lower FEV1%, Caucasian race, male gender, and increased airway wall thickness are associated with CB. These data provide clinical and radiologic correlations to the clinical phenotype of CB.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available